OptiNose

OptiNose — Q2 2021 Earnings Presentation

18 slides from OptiNose's earnings presentation, Aug 11, 2021

  1. Slide 1: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company C o r p o r a t e P r e s e n t a t i o n A u g u s t 1 1 , 2 0 2 1 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this

  3. Slide 3: Key Takeaways and Q2 2021 Highlights

    3 Key Takeaways and Q2 2021 Highlights Q2 2021 Performance Aligned with Company Guidance Multiple Factors Support Continued Revenue Growth in 2021 Enrollment Complete in First CS Trial with Data Expected in Q1 2022 Market Opportunity in CS is Significantly Larger than NP +79% XHANCE Net Revenue Grow

  4. Slide 4: XHANCE New and Total Prescriptions

    4 XHANCE New and Total Prescriptions XHANCE New Prescriptions increased 55% and Total Prescriptions increased 33% from Q2 2020 to Q2 2021 Estimated based on monthly prescription data from third parties and XHANCE preferred pharmacy network. The Market on this slide is defined as the sum of all intra

  5. Slide 5: XHANCE Market Share & Prescribers by Prescribing Frequency

    5 XHANCE Market Share & Prescribers by Prescribing Frequency The Market on this slide is defined as the sum of all intranasal steroid prescriptions written by physicians in the XHANCE target physician audience of approximately 18,000 physicians. Estimated based on monthly prescription data from thir

  6. Slide 6: Q2 2021 Financial Update

    optinose’_ SSS Q2 2021 Financial Update

  7. Slide 7: Financial Review – Second Quarter 2021

    7 Financial Review – Second Quarter 2021 XHANCE Net Revenue Increased 79% and Average Net Revenue per TRx Increased from $164 to $221 from Q2 2020 to Q2 2021 $10.3 $18.4 Q2 '20 Q2 '21 ($M) +79% $164 $221 Q2 '20 Q2 '21 +35% Net Revenue Average Net Revenue per TRx

  8. Slide 8: Full Year 2021 Financial Guidance

    8 Full Year 2021 Financial Guidance  XHANCE Net Revenue and Average Net Revenue per Prescription ‒ FY 2021 expected to be at least $80 million ‒ FY 2021 average net revenue per prescription expected to exceed $200  Operating Expense (GAAP) expected to be between $137 – $142 million ‒ Approximately

  9. Slide 9: Pipeline Updates

    optinose’_ SSS Pipeline Updates

  10. Slide 10: Chronic Sinusitis Pivotal Study Design Summary

    10 EDS Placebo 372 μg Run-in to ensure ability to use patient symptom diary and presence of baseline symptoms Day 1 Week 24 Double Blinded Phase En d of St ud y Week 12Week 8 Chronic Sinusitis Pivotal Study Design Summary Randomized, double-blind, placebo-controlled, parallel-group, multicenter stud

  11. Slide 11: XHANCE Chronic Sinusitis Program

    11 XHANCE Chronic Sinusitis Program  Enrollment in trial -3205 is complete  In June we conducted a planned, blinded, interim analysis (IA) to assess variance in APOV (the CT scan co-primary endpoint) in trial -3205 – The observed variance in the IA is less than the variance assumed for the purpose

  12. Slide 12: OPN-019 Pilot Study

    12 OPN-019 Pilot Study  In early July we received approval from regulatory authorities in Mexico to proceed with conduct of a randomized, adaptive proof of concept single-dose study to evaluate change in viral load after use of OPN-019 by adults with COVID-19  Study drug was made available in Mexi

  13. Slide 13: Chronic Sinusitis and the Primary Care Opportunity

    Chronic Sinusitis and the Primary Care Opportunity

  14. Slide 14: Successful CS Development and a Primary Care Partner Could Enable Promotion of XHANCE

    14 Successful CS Development and a Primary Care Partner Could Enable Promotion of XHANCE to up to 30 Million Patients  Approximately 1 Million patients with nasal polyps (NP) are treated by specialty physicians who are the current focus of our sales call plans – Specialty physician preference share

  15. Slide 15: Closing Remarks

    optinose’_ SSS Closing Remarks

  16. Slide 16: Key Takeaways and Q2 2021 Highlights

    16 Key Takeaways and Q2 2021 Highlights Q2 2021 Performance Aligned with Company Guidance Multiple Factors Support Continued Revenue Growth in 2021 Enrollment Complete in First CS Trial with Data Expected in Q1 2022 Market Opportunity in CS is Significantly Larger than NP +79% XHANCE Net Revenue Gro

  17. Slide 17: Investor Relations – Optinose

    17 Investor Relations – NASDAQ: OPTN Optinose Investor Contact Jonathan Neely, VP, Investor Relations and Business Development 267-521-0531 [email protected] At 30 June 2021: – $94 million in cash – Long-term debt: $130 million – 53.1 million common shares o/s – 11.4 million options, warrants &

  18. Slide 18: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company C o r p o r a t e P r e s e n t a t i o n A u g u s t 1 1 , 2 0 2 1

OptiNose — Q2 2021 Earnings Presentation on 6ix